<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2027-0119</journal-id>
<journal-title><![CDATA[Urología Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Urol. Colomb.]]></abbrev-journal-title>
<issn>2027-0119</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2027-01192024000100020</article-id>
<article-id pub-id-type="doi">10.24875/ruc.22000005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Características de pacientes con tumor germinal testicular tipo seminoma y masa retroperitoneal posquimioterapia]]></article-title>
<article-title xml:lang="en"><![CDATA[Characteristics of patients with seminoma-type testicular germ cell tumor and retroperitoneal mass post-chemotherapy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampo-Gómez]]></surname>
<given-names><![CDATA[María A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Matson]]></surname>
<given-names><![CDATA[María C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[Marino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Varela]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Rosario Departamento de Urología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología Departamento de Urología Oncológica ]]></institution>
<addr-line><![CDATA[Bogotá D.C]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2024</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>20</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2027-01192024000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2027-01192024000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2027-01192024000100020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Describir las características clínicas y patológicas de los pacientes con tumor germinal testicular tipo seminoma con masa residual posquimioterapia (post-QT) con marcadores tumorales negativos llevados a linfadenectomía retroperitoneal (LRP).  Método: Se incluyeron pacientes con TGTS y masa residual post-QT entre el año 2007-2021 en nuestra institución. Los datos fueron obtenidos mediante la evaluación retrospectiva de nuestra base de datos electrónica.  Resultados: Nueve pacientes cumplieron con los criterios de inclusión. Según la estadificación del TNM, seis pacientes eran pT1, mientras que tres (33,3%) eran N2 y N3. La mayoría de los pacientes, cinco en total, tenían un estadio clínico IIC y todos los pacientes se clasificaron como riesgo bueno según la clasificación del International Germ Cell Cancer Collaborative Group (IGCCCG). Se observaron cinco pacientes, tres fueron intervenidos con LRP y solo uno recibió QT. Solo en dos pacientes llevados a LRP se logró una resección completa de la masa y se encontró tumor viable en el 66,6% de los pacientes llevados a cirugía.  Conclusión: En nuestra experiencia la LRP es viable en este tipo de pacientes, logrando la resección completa en la mayo ría de los casos. Cuando no se logra una resección completa es imprescindible ofrecer tratamientos adicionales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: We aim to describe the clinical and pathological characteristics of patients with seminomatous germ cell tumour (SGCT) and residual masses following chemotherapy (CTX) with negative tumor markers taken to retroperitoneal lymph node dissection (RLND).  Method: We included patients with SGCT and had a residual mass after CTX between 2007 and 2021 in our institution. Data was obtained in a retrospective fashion from our electronic database.  Results: A total of 9 patients match the inclusion criteria. Above 66% of patients were Pt1, most of them were N2 (33.3%) and N3 (33.3%), 55.5% had a IIC clinical stage and all the patients had good risk following the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. The majority of the patients were observed (55.5%), 33.3% were taken to RLND and one patient received CTX. Almost 66.6% of the patients taken to RLND had a complete resection of the mass and had viable tumor in 66.6% of the cases.  Conclusions: In our retrospective study the RLND is a good option for these patients and allows a complete resection in most of the cases. When a complete resection is not possible is necessary to offer additional treatments.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tumor germinal]]></kwd>
<kwd lng="es"><![CDATA[Seminoma]]></kwd>
<kwd lng="es"><![CDATA[Masa residual]]></kwd>
<kwd lng="es"><![CDATA[PET-CT]]></kwd>
<kwd lng="es"><![CDATA[Tumor viable]]></kwd>
<kwd lng="es"><![CDATA[Linfadenectomía retroperitoneal]]></kwd>
<kwd lng="en"><![CDATA[Germ-cell tumor]]></kwd>
<kwd lng="en"><![CDATA[Seminoma]]></kwd>
<kwd lng="en"><![CDATA[Residual mass]]></kwd>
<kwd lng="en"><![CDATA[PET-CT]]></kwd>
<kwd lng="en"><![CDATA[Viable tumor]]></kwd>
<kwd lng="en"><![CDATA[Retroperitoneal lymph node dissection]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puc]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Heelan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mazumdar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Scheinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Vlamis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>1996</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>454-60</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Heelan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fair]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Whitmore]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Sogani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy]]></source>
<year>2019</year>
<volume>5</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1064-70</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albany]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kesler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cary]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of residual mass in germ cell tumors after chemotherapy]]></article-title>
<source><![CDATA[Curr Oncol Rep.]]></source>
<year>2019</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cathomas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Klingbiel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bernard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lorch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Morelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an international global germ cell cancer group registry]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laguna]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Albers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Algaba]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Boormans]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Nardo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[EAU Guidelines on Testicular Cancer]]></source>
<year>2022</year>
<publisher-name><![CDATA[European Association of Urology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavery]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Sharp]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Pohar]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors]]></article-title>
<source><![CDATA[Ther Adv Urol.]]></source>
<year>2009</year>
<volume>1</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>199-207</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conduit]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[TT]]></given-names>
</name>
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Toner]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Goad]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrentschuk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up]]></article-title>
<source><![CDATA[Cancer Imaging]]></source>
<year>2022</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalemci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kizilay]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ergun]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Aliyev]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Simsir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post chemotherapy retroperitoneal residual mass resection for germ cell testicular tumors: A single-center experience]]></article-title>
<source><![CDATA[Rev Assoc Med Bras]]></source>
<year>2022</year>
<volume>68</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>524-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gurney]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Znaor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Laversanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sarfati]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International trends in the incidence of testicular cancer: les sons from 35 years and 41 countries]]></article-title>
<source><![CDATA[Eur Urol.]]></source>
<year>2019</year>
<volume>76</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>615-23</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Becherer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bokemeyer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stoiber]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Oechsle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sellner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2-18 fluoro-deoxy-D-glucose positron emission tomogra phy is a reliable predictor for viable tumor in post chemotherapy semi-noma: An update of the prospective multicentric Sempet trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2004</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1034-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Thuer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Polyakov]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis]]></article-title>
<source><![CDATA[Eur Urol.]]></source>
<year>2008</year>
<volume>53</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>260-72</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Sheinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puc]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Heelan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bajorin]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Mencel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surgery for a post chemotherapy residual mass in seminoma]]></article-title>
<source><![CDATA[J Urol.]]></source>
<year>1997</year>
<volume>157</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>860-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
